How Much Does De Novo Sequencing Cost? Key Factors to Consider Before Starting
-
project scoping before sample submission
-
sample feasibility feedback
-
digestion and acquisition strategy matched to the reporting goal
-
prioritized analysis of high-quality spectra for peptide identification
-
manual review of critical peptide assignments
-
clear separation of high-confidence and tentative sequence calls
-
practical recommendations for validation or follow-up experiments
-
submitting a complex lysate when enrichment was needed
-
requesting full-length coverage without enough sample amount
-
skipping replicate or overlap design to save upfront cost
-
choosing a report format that lacks the evidence needed for downstream use
-
delaying validation planning until after ambiguous sequence calls appear
-
What exact sequence region must be confirmed?
-
Is the sample purified, enriched, or highly complex?
-
Is the protein known, engineered, or completely unknown?
-
Are modifications, variants, or blocked termini expected?
-
Is one enzyme sufficient, or is overlap coverage required?
-
What level of manual review and annotated reporting is needed?
-
Will the result support exploratory analysis, cloning, publication, or QC documentation?
-
Is there enough sample for repeat digestion or replicate MS if needed?
Introduction
Researchers evaluating de novo sequencing often ask for a single price before the sample details are clear. That question is understandable. Grant budgets, project timelines, and vendor comparisons all depend on cost predictability. However, the service is rarely sold as a one-size- fits-all assay. The price depends on what must be sequenced, how clean the sample is, how much coverage is required, and how much manual interpretation and validation are included in the final report.
A peptide-level confirmation for one enriched protein band is a different project from full antibody variable-region sequencing or unknown protein characterization with no reference sequence. Treating these projects as equivalent leads to under-budgeting, repeated sample submission, or disappointment when the deliverable does not match the biological need. The better question is not only "How much does it cost?" but "What cost drivers apply to this study, and what level of sequence evidence do we actually need?"
Related Services
| Research Need | Recommended Service Direction |
|---|---|
| Sequence peptides without database matching | De Novo Sequencing Service |
| Build full protein sequence coverage by MS | De Novo Protein Sequencing Service |
| Sequence antibody variable regions | De Novo Antibody Sequencing Service |
| Analyze proteins with no reliable reference | Unknown Proteins Sequencing Service |
| Support broader MS sequence confirmation | Protein Sequencing Service by Mass Spectrometry |
For projects where scope, sample quality, or reporting depth is still undefined, MtoZ Biolabs can help scope project requirements and provide a project-based quote before sample submission.
Why De Novo Sequencing Quotes Vary
Unlike routine database-search proteomics, this workflow often includes targeted sample handling, selective MS/MS acquisition, manual spectrum review, and sequence assembly. These steps add value, but they also make pricing project-specific. Two samples that look similar on a gel can differ sharply in cost if one needs a short peptide confirmation and the other needs overlapping coverage across a full chain.
Quotes also vary because deliverables differ. Some clients need a candidate peptide list. Others need a publication-ready sequence map, annotated spectra, ambiguous residue flags, and recommendations for follow-up validation. A lower-cost option that excludes manual review may be appropriate for exploratory work. A higher-cost option with expert interpretation is often necessary for antibody development, clone selection, or biopharmaceutical documentation.
Key Cost Factors to Evaluate Before Starting
The most important pricing drivers can be grouped into five categories. Understanding these categories helps researchers compare proposals fairly and avoid paying for unnecessary depth or, worse, underfunding a project that requires more evidence.
1. Sample Type and Purity
Purified protein, enriched gel band, antibody chain fraction, or complex mixture each changes preparation effort. Cleaner input reduces repeat runs and interpretation time. Heavy contamination or low protein amount can increase fractionation, repeat digestion, and MS acquisition time.
2. Sequence Coverage Depth
Confirming one peptide region costs less than assembling a domain, full protein, or complete antibody variable region. Coverage depth is usually the largest scientific driver of project scope and therefore cost.
3. MS Acquisition Depth
More LC-MS/MS time, additional fractionation, complementary enzyme digests, and replicate runs improve confidence but increase instrument and analysis time. High- complexity samples often need more acquisition depth than a single enriched band.
4. Manual Interpretation
Automated de novo tools are only the starting point. Expert spectrum review, overlap assembly, and ambiguous residue assessment are often required for reliable reporting. Projects with higher interpretation burden typically cost more than unattended software output alone.
5. Reporting and Validation
Deliverables such as annotated spectra, overlap maps, sequence confidence flags, and validation recommendations add value for high-stakes decisions. Optional follow-up validation planning or orthogonal method support can also affect the final quote.
Figure 1. Main factors that influence project cost
How Project Scope Changes the Budget
Project scope is the practical bridge between scientific need and price. A narrow scope can keep costs controlled. A broad scope may be necessary, but it should be chosen deliberately rather than by default.
Lower-scope projects typically include one enriched sample, limited digestion strategy, focused MS/MS acquisition, and confirmation of a short peptide region. These projects suit early feasibility checks or targeted sequence questions when the sample is reasonably pure.
Moderate-scope projects may require multiple enzymes, overlapping peptide coverage, and manual review across a defined protein domain. They are common when a recombinant product or expression construct must be checked against an expected sequence with possible local variation.
Higher-scope projects often involve full protein or antibody chain assembly, poorly annotated samples, low input amount, or reporting requirements that support cloning, publication, or biopharmaceutical documentation. These projects usually require more digestion design, more MS time, and more expert interpretation.
Figure 2. How project scope affects complexity and cost
Researchers should define scope before comparing vendor quotes. A quote based on "one gel band" is not comparable to a quote based on "full variable-region antibody sequencing with overlap coverage and annotated reporting."
What You Are Paying For in a Quality Service
Price should be evaluated together with deliverable quality. A lower quote may exclude steps that matter for the final decision. A higher quote may reflect real value if it includes sample assessment, optimized digestion, selective MS/MS acquisition, manual review, and a report that can be used downstream.
A strong MS sequence service typically provides:
These elements reduce the risk of paying twice because the first run did not produce usable sequence evidence.
Timeline and Hidden Cost Risks
Time is also a cost factor. Rush requests, repeat sample preparation, and rescuing poorly planned experiments can increase total project expense more than an appropriately scoped first attempt. Common hidden cost risks include:
Planning the reporting goal and validation path before sample submission often saves both money and calendar time.
Questions to Ask Before Requesting a Quote
Use the following questions to prepare a useful quote request:
The more clearly these questions are answered, the more accurate the initial quote and project plan will be.
Figure 3. Pre-start checklist for scoping project cost
How to Get a More Accurate Quote
The most reliable quotes are based on project scope rather than sample count alone. Share sample type, estimated purity, target protein information, expected coverage, and reporting needs with the service provider. If available, a gel image, prior identification result, or expected construct sequence can help the team estimate digestion strategy and analysis depth.
For uncertain projects, a staged approach may be cost-effective. A pilot run on limited material can test digestion quality, spectrum usefulness, and achievable coverage before committing to full chain assembly. This approach is especially useful for unknown proteins, difficult membrane proteins, and antibody sequencing projects with limited sample.
Frequently Asked Questions
1. Is there a standard price for de novo sequencing?
No. Pricing is usually project-based because sample type, coverage depth, MS time, and reporting requirements vary widely. A short peptide confirmation and a full antibody sequencing project should not be expected to cost the same.
2. What usually increases project cost the most?
Coverage depth, sample complexity, and manual interpretation burden are often the largest drivers. Full-chain assembly, low-purity samples, and high-confidence reporting requirements typically increase cost more than simple instrument time alone.
3. Can I reduce cost without losing scientific value?
Yes. Define the minimum sequence evidence needed, improve sample purity, provide background information, and use a staged pilot when appropriate. Reducing unnecessary coverage or reporting depth can control cost if the downstream decision does not require full-chain proof.
4. Is this approach more expensive than database search?
Usually yes for comparable sample input, because sequence-from-spectrum analysis often includes selective analysis and manual interpretation. However, when the reference sequence is unavailable or unreliable, de novo sequencing may be the only practical route to usable sequence evidence.
5. What information should I send before requesting a quote?
Send sample type, amount, purity estimate, organism or expression system, target protein details, desired coverage, expected modifications or variants, and the intended use of the final report. These details help providers estimate digestion, MS, and interpretation effort accurately.
Conclusion
Project cost depends on sample quality, coverage depth, MS acquisition strategy, manual interpretation, and reporting requirements. Projects with narrow sequence goals and clean samples are usually more affordable than full-chain antibody sequencing or unknown protein characterization with no reference. The most cost-effective approach is to define the reporting goal early, share complete sample information, and request a scoped quote before submission.
If you need help estimating project scope and budget for peptide or protein sequence work, contact MtoZ Biolabs to discuss sequence-from-spectrum analysis, antibody sequencing, unknown protein analysis, or a customized MS-based sequence workflow.
How to order?
